

INFECTIOUS DISEASES PUBLICATIONS 2026

1. Manji S, Saxinger L, Cook L, McDonald T, Dickinson JA, Saini V. A population-based study of community antibiotic prescribing patterns in Alberta from 2010 to 2017: Implications for antibiotic stewardship. *Can J Public Health*. 2026;117(3):495-512. doi:10.17269/s41997-025-01104-7 (Saxinger L)
2. Harrison R, Reid EK, Allen UD, et al. AMMI Canada seasonal influenza guideline update 2025–26: Some questions answered. *Journal of the Association of Medical Microbiology and Infectious Disease Canada*. 2026;11(1):1-8. doi:10.3138/jammi-2026-0105 (Harrison R)
3. Riopel ND, Andrievskaia O, DeWith NI, et al. Animal-Adapted Tuberculosis Strains – a One-World Problem, a One Health Solution? *Curr Infect Dis Rep*. 2026;28(1):16. doi:10.1007/s11908-026-00887-1 (Cooper R)
4. Leal J, Zhang Z, Armstrong L, et al. Antimicrobial-resistant organism admission screening adherence using a clinical information system and its impact on methicillin-resistant *Staphylococcus aureus* rates in a provincial healthcare system. *American Journal of Infection Control*. Published online January 2026:S0196655326000143. doi:10.1016/j.ajic.2026.01.007 (Smith S)
5. Gratrix J, Ives N, Egan C, et al. Assessing the Impact of an Sexually Transmitted Infections Nurse on the Delivery of Sexually Transmitted Infections/Human Immunodeficiency Virus Services in an Inner-City Emergency Department Using a Human Immunodeficiency Virus/Syphilis Point-of-Care Test During a Syphilis Outbreak in Alberta, Canada. *Sexually Transmitted Diseases*. 2026;53(8):581-587. doi:10.1097/OLQ.0000000000002333 (Singh A)
6. Garland A, Dodek P, Thavorn K, et al. Canadian Metadata Catalogue for Health Science Research. *IJPDS*. 2026;11(1). doi:10.23889/ijpds.v11i1.3372 (Sligl W)
7. The *Staphylococcus aureus* Network Adaptive Platform (SNAP) Trial Group. Cefazolin for Methicillin-Susceptible *Staphylococcus aureus* Bacteremia. *N Engl J Med*. 2026;394(23):2329-2339. doi:10.1056/NEJMoa2506905 (Smith S)
8. Ong SWX, Pinto R, Mahar RK, et al. Comparing different methods for analysing hierarchical composite endpoints: two illustrative case studies with post hoc analyses of the BALANCE (Bacteraemia Antibiotic Length Actually Needed for Clinical Effectiveness) and CAMERA2 (Combination Antibiotics for methicillin-resistant *Staphylococcus aureus*) randomized clinical trials. *Clinical Microbiology and Infection*. 2026;32(3):482-489. doi:10.1016/j.cmi.2025.11.027 (Smith S, Doucette K)
9. Mosley SR, Lapa N, Namdar A, et al. Cytosolic DNA structures produced by mismatch repair deficiency coordinate anti-tumor immunity in colorectal cancer. *Cell Reports*. 2026;45(3):117012. doi:10.1016/j.celrep.2026.117012 (Meier-Stephenson V)
10. Herrero JI, Agüero F, Manzardo C, et al. De Novo Cancer in Liver Transplant Patients With HIV Infection: A Multicenter Nationwide Cohort Study. *Clinical Infectious Diseases*. 2026;83(1):160-169. doi:10.1093/cid/ciag124 (Cervera C)

11. Joseph P, Dehghan M, Ezekowitz JA, et al. Diet and Clinical Outcomes in a Heart Failure Population. *JACC: Heart Failure*. 2026;14(4):102728. doi:10.1016/j.jchf.2025.102728 (Smith S)
12. Wang R, Quinn RR, Ravani P, et al. Duration of Pneumocystis jirovecii pneumonia prophylaxis in adult kidney transplant recipients and outcomes: A population-based study. *American Journal of Transplantation*. 2026;26(4):880-891. doi:10.1016/j.ajt.2025.11.010 (Doucette K)
13. Yahav D, Pinto R, Cook D, et al. Duration of Therapy for *Pseudomonas aeruginosa* Bacteremia—A Post Hoc Subgroup Analysis From the BALANCE Randomized Controlled Trial. *Clinical Infectious Diseases*. 2026;83(1):41-47. doi:10.1093/cid/ciag144 (Sligl W)
14. Aponte-Hao S, Vu K, Randall JR, et al. Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID -19 Encounter: A Retrospective Cohort Study From Alberta, Canada. *Pharmacoepidemiology and Drug*. 2026;35(1):e70302. doi:10.1002/pds.70302 (Saxinger L)
15. Gitau Z, Suarez-Ariza C, Arango-Uribe M, et al. Epidemiology of hepatitis C in Alberta, Saskatchewan, and Manitoba compared to Canada, 1980–2023. *Journal of Infection and Public Health*. 2026;19(3):103148. doi:10.1016/j.jiph.2026.103148 (Singh A)
16. Romanowski K, Brode SK, Cook VJ, et al. Estimated impact of timely, guideline-adherent tuberculosis screening in primary care settings among new permanent residents to British Columbia, Canada: A population-based study. *Can J Public Health*. Published online April 13, 2026. doi:10.17269/s41997-026-01198-7 (Cooper R)
17. Thompson LA, Gratrix J, Ives N, et al. Evaluating the Impact of Implementing and Scaling-Up the Use of Syphilis Rapid/Point-of-Care Tests: An Interrupted Time Series Analysis of New Syphilis Positivity Rates in Alberta, Canada. *Clinical Infectious Diseases*. 2026;82(4):e826-e835. doi:10.1093/cid/ciaf651 (Singh A)
18. McGill E, Lee D, Quach C, et al. Hospital characteristics associated with healthcare-associated viral respiratory infection rates in a Canadian acute care network. *Infect Control Hosp Epidemiol*. Published online July 22, 2026:1-9. doi:10.1017/ice.2026.10490 (Smith S)
19. Arango-Uribe M, Keynan R, Gitau Z, et al. Increasing rates of Chlamydia trachomatis infection in Alberta, Saskatchewan, and Manitoba compared to Canada overall, between 1991 and 2022. *Infectious Diseases Now*. 2026;56(3):105263. doi:10.1016/j.idnow.2026.105263 (Singh A)
20. Lau VI, Hammal F, Zampieri FG, et al. Intensive Care Unit and Hospital Mortality for non-COVID Critically ill Patients Before, and During the COVID-19 Pandemic in Alberta Hospitals: Retrospective, Observational Cohort Study. *J Intensive Care Med*. Published online July 6, 2026:08850666261465346. doi:10.1177/08850666261465346 (Sligl W)
21. Harrison R, Reid EK, Allen UD, et al. Mise à jour de l'AMMI Canada sur la grippe

saisonnière de 2025–26 : Réponses à quelques questions. *Journal of the Association of Medical Microbiology and Infectious Disease Canada*. 2026;11(1):9-17.
doi:10.3138/jammi-2026-0105-FR (Harrison R)

22. Suarez-Ariza C, Gitau Z, Arango-Urbe M, et al. *Neisseria gonorrhoeae* infection and antimicrobial resistance in Alberta, Saskatchewan, and Manitoba compared to Canada between 1980 and 2022. *Epidemiol Infect.* 2026;154:e9. doi:10.1017/S0950268825100885 (Singh A)
23. Henry B, Walth LN, Kothari S, et al. Non-*Aspergillus fumigatus* mould infections in lung transplant recipients: an international, multicentre, case–control study. *The Lancet Microbe*. Published online July 2026:101352. doi:10.1016/j.lanmic.2026.101352 (Kabbani D)
24. Tan C, Bharat A, McGill E, et al. Preparedness for *Candida auris* in Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals, 2024. *Infect Control Hosp Epidemiol.* 2026;47(1):39-45. doi:10.1017/ice.2025.10228 (Smith S)
25. Riunga F, Cervera C, Kabbani D. Pretransplant screening for infections in lung and heart transplant candidates. *JHLT Open.* 2026;11:100409. doi:10.1016/j.jhlto.2025.100409 (Cervera C, Kabbani D)
26. Mayer EF, Falsey AR, Wolfe CR, et al. Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345. *Clinical Infectious Diseases.* 2026;82(5):e1112-e1121. doi:10.1093/cid/ciag108 (Kabbani D)
27. Leeies M, Hrymak C, Mooney O, et al. Sexual and Gender Minorities in Organ and Tissue Donation and Transplantation (OTDT): A Survey of Canadian OTDT Health Care Workers. *Can J Kidney Health Dis.* 2026;13:20543581251412804. doi:10.1177/20543581251412804 (Doucette K)
28. Stotts C, Corrales-Medina VF, deKemp RA, et al. Targeting Vascular Inflammation In Patients with Community-Acquired Pneumonia (TIN-CAP): protocol for a multicentre, randomised, double-blind, placebo-controlled trial. *BMJ Open.* 2026;16(3):e114239. doi:10.1136/bmjopen-2025-114239 (Sligl W)
29. Montagnes DJS, Dacks JB, Dolan JR, et al. The value of learned societies in the biological sciences: benefits, threats, and futures. *BMC Biol.* 2026;24(1):114. doi:10.1186/s12915-026-02583-x (Dacks J)
30. Fernández-García OA, Co J, Suandork T, Leeies M, Doucette KE. Trends in Increased Infection Risk Deceased Organ Donors. A Two-Centre Retrospective Study. *Can J Kidney Health Dis.* 2026;13:20543581261463456. doi:10.1177/20543581261463456 (Fernandez-Garcia O, Doucette K)
31. Grant A, Kabbani D, Vuong A, et al. Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations. *Pharmacoeconomics Open.* Published online January 29, 2026. doi:10.1007/s41669-026-00639-w (Kabbani D)

32. Howarth A, Tunis M, Jensen C, Pierre S, Crane F, Siu W, Harrison R on behalf of the National Advisory Committee on Immunization (NACI). Summary of approach to inclusive language in vaccine guidance from the National Advisory Committee on Immunization (NACI). Can Commun Dis Rep 2026;52(4):107–15.
doi.10.14745/ccdr.v52i04a01 (*Harrison, R*)